Formulation and Evaluation of Tenofovir Disoproxil Fumarate Mouth Dissolving Thin Films

Abstract

A nucleotide analogue reverse transcriptase inhibitor, tenofovir disoproxil fumarate is used for the treatment of hepatitis B and the management of HIV-1 infection. This study set out to develop Tenofovir mouth dissolving films using a variety of polymers in the hopes of helping patients who have trouble swallowing traditional dosage forms, increasing the drug's bioavailability and facilitating its rapid onset of action, and ultimately helping those patients. Additionally, children, the elderly, and patients with developmental disabilities, in addition to those with mental illness, benefit from the greater accessibility of MDFs. We used a solvent casting process to formulate the MDFs. The optimised MDF is subjected to a battery of tests, including those for uniformity of weight and drug content, thickness, folding endurance, surface pH, in vitro disintegration time, tensile strength and percent elongation, scanning electron microscopy, in vitro dissolution, stability, taste evaluation by spitting, comparison with marketed formulation, drug release kinetics, and optimisation. after contrast, the optimised MDF's % CDR was determined to be 99.37±2.06% after 10 minutes, whereas the market formulation reached 81.48±1.54% after 12 minutes. These results proved that the MDFs that were loaded with Tenofovir were effective.